Doc type: Policy Directive
Compliance with this policy directive is mandatory.
Doc No.: PD2005_624
Functional Group - Sub Group:
Corporate Administration - Governance
Clinical/ Patient Services - Pharmaceutical
Clinical/ Patient Services - Medical Treatment
Clinical/ Patient Services - Nursing and Midwifery
Population Health - Pharmaceutical
Summary
This policy replaces Information Bulletin 93/31. Policy and risk management strategies to reduce the risk of error when oral methotrexate is prescribed, dispensed and administered for the treatment of inpatients or outpatients. Oral methotrexate is considered a high alert medicine due to the potential for error with its once a week dosage regimen, which is unusual compared to the daily dosing of most other medicines.
Date of Publication: 26 September 2005
Replaces: N/A
Author Branch: Pharmaceutical Services
This document applies to: Area Health Services/Chief Executive Governed Statutory Health Corporation, Board Governed Statutory Health Corporations, Affiliated Health Organisations - Non Declared, Public Health System Support Division, Community Health Centres, Divisions of General Practice, Government Medical Officers, Private Hospitals and Day Procedure Centres, Private Nursing Homes, Public Hospitals
Audience: Administration, medical, pharmacy, nursing
Distributed to: Public Health System, Community Health Centres , Divisions of General Practice, Government Medical Officers, Health Professional Associations and Related Organisations, NSW Ambulance Service , NSW Department of Health, Public Hospitals, Private Hospitals and Day Procedure Centres , Private Nursing Homes, Tertiary Education Institutes
Review Date: 26 September 2010
File No: 99/5022
Previous reference: N/A
Status: Active
File link: Methotrexate - Safe use of Oral Methotrexate
File size: 51Kb
|
 |
